Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.57 |
| ▸ | MMP2 | P08253 | 6/20 | 0.57 |
| ▸ | MMP14 | P50281 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MMP10 | P09238 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618420 | 0.87 | FLT3 (0.46) | MMP13 | |
| SCHEMBL14573304 | 0.81 | NR4A1 (0.42) | MMP13MMP2MMP14KDM4EHRH3 | |
| SCHEMBL5619095 | 0.80 | FLT3 (0.49) | SMN1; SMN2HRH3 | |
| SCHEMBL31380901 | 0.78 | MMP13 (0.62) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL14573305 | 0.77 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL5618652 | 0.76 | SYK (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10LMNA | |
| SCHEMBL5618954 | 0.74 | FLT3 (0.51) | — | |
| SCHEMBL25024764 | 0.72 | MMP13 (0.78) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL15642864 | 0.71 | MMP13 (1.00) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL5401140 | 0.71 | FLT3 (0.55) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | MMP13 3949/4885MMP2 3821/4885MMP14 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.